Use of oral contraceptives in Germany: Prevalence, determinants and use-associated health correlates. Results of National Health Surveys from 1984 to 1999

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 134, Issue 1, 2007, Pages 57-66

  Du, Yong ^a   Melchert, Hans Ulrich ^a   Schäfer Korting, Monika ^b  

^a ROBERT KOCH INSTITUTE   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Germany; National Health Surveys; Oral contraceptives; Population representative data

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GERMANY; HEALTH STATUS; HEALTH SURVEY; HUMAN; LIFESTYLE; NATIONAL HEALTH SERVICE; ORAL CONTRACEPTION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 34548301625     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2007.01.007     Document Type: Article

References (32)

1. Tanis B.C., van den Bosch M.A.A.J., Kemmeren J.M., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 345 (2001) 1787-1793
2. Gillum L.A., Mamidipudi S.K., and Johnston S.C. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 284 (2000) 72-78
3. Farmer R.D., Lawrenson R.A., Todd J.C., et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 49 (2000) 580-590
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 347 (1996) 1713-1727
5. Dunn N., Thorogood M., Faragher B., et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 12 (1999) 1579-1583
6. Marchbanks P.A., McDonald J.A., Wilson H.G., et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 346 (2002) 2025-2032
7. Petitti D.B., Sidney S., Bernstein A., Wolf S., Quesenberry C., and Ziel H.K. Stroke in users of low-dose oral contraceptives. N Engl J Med 335 (1996) 8-15
8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
9. http://msnbc.msn.com/id/6291053, accessed on 25 October 2004.
10. La Vecchia C., and Franceschi S. Oral contraceptives and ovarian cancer. Eur J Cancer Prev 8 (1999) 297-304
11. The Cancer and Steroid Hormone Study Group. Combination oral contraceptive use and the risk of endometrial cancer. The cancer and steroid hormone study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 257 (1987) 796-800
12. Lundberg V., Tolonen H., Stegmayr B., Kuulasmaa K., Asplund K., and WHO MONICA Project. Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. Maturitas 48 (2004) 39-49
13. GCP Study Group. The German Cardiovascular Prevention Study (GCP): design and methods. GCP Study Group. Eur Heart J 9 (1988) 1058-1066
14. Schwerpunktheft: Bundes-Gesundheitssurvey 1998 -Erfahrungen, Ergebnisse und Perspektiven (Translation: German National Health Interview and Examination Survey -experiences, results and perspectives). Gesundheitswesen 61 (Special Issue 2) 1999; 55-222.
15. Heinemann K., Moehner S., Lewis M., Assmann A., Garbe E., and Heinemann L.A. Trends of OC use 1980-1999 in a German cohort of women. Zentralbl Gynäkol 124 (2002) 128-131
16. Oddens B.J. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. Contraception 59 (1999) 277-286
17. Spitzer W.O., Lewis M.A., Heinemann L.A., Thorogood M., and MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312 (1996) 83-88
18. Piccinino L.J., and Mosher W.D. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 30 (1998) 4-10 46
19. Melchert H.U., and Knopf H. Daten der Nationalen Untersuchungssurveys zum Verbrauch oraler Kontrazeptiva (OC) in West- und Ostdeutschland (Data of National Health Surveys for oral contraceptive use in West and East Germany). In: Bärbel-Maria Bellach (Hrsg.) (Ed). Die Gesundheit der Deutschen (Band 2): Zusammenhänge zwischen Gesundheit und Lebensstil, Umwelt und soziodemografischen Faktoren-Eine Auswertung von Surveydaten (1996), Robert-Koch Institute, Berlin 133-148 ISBN 3-89606-016-3
20. Mukherjea M., Mukherjee P., and Biswas R. Long-term contraception with Depo-Provera: a clinical evaluation. Int J Fertil 25 (1980) 122-126
21. Lloyd T., Lin H.M., Matthews A.E., Bentley C.M., and Legro R.S. Oral contraceptive use by teenage women does not affect body composition. Obstet Gynecol 100 (2002) 235-239
22. Egarter C., Topcuoglu M.A., Imhof M., and Huber J. Low dose oral contraceptives and quality of life. Contraception 59 (1999) 287-291
23. Larsson G., Milsom I., Lindstedt G., and Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 46 (1992) 327-334
24. The ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Human Reproduction Update 11 (2005) 513-525
25. Davis A., Godwin A., Lippman J., Olson W., and Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 96 (2000) 913-920
26. Task Force for Epidemiological Research on Reproductive Health. Effects of contraceptives on hemoglobin and ferritin. Contraception 58 (1998) 262-273
27. WHO. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. 2nd ed. (2000), World Health Organization, Geneva
28. Chasan-Taber L., Willett W.C., Manson J.E., et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 94 (1996) 483-489
29. Scharnagl H., Petersen G., Nauck M., Teichmann A.T., Wieland H., and Marz W. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception 69 (2004) 105-113
30. Mantel-Teeuwisse A.K., Kloosterman J.M., Maitland-van der Zee A.H., Klungel O.H., Porsius A.J., and de Boer A. Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 24 (2001) 443-456
31. Lobo R.A., Skinner J.B., Lippman J.S., and Cirillo S.J. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril 65 (1996) 1100-1109
32. Du Y., Melchert H.U., and Schäfer-Korting M. Hormone replacement therapy in Germany-determinants and possible health-related outcomes: results of National Health Surveys from 1984 to 1999. Maturitas 52 (2005) 223-234